Загрузка...
Quantile regression to characterize solanezumab effects in Alzheimer's disease trials
INTRODUCTION: In two solanezumab trials for mild-to-moderate Alzheimer's disease (AD) dementia, 27% of patients had biomarker confirmation of amyloid status. Of these, approximately 25% of mild patients and approximately 10% of moderate patients were amyloid negative and, as a group, did not ex...
Сохранить в:
| Опубликовано в: : | Alzheimers Dement (N Y) |
|---|---|
| Главные авторы: | , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Elsevier
2016
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5651345/ https://ncbi.nlm.nih.gov/pubmed/29067306 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.trci.2016.07.005 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|